Overview New real-world data from three health systems in Colorado and Utah suggest that receiving remdesivir (RDV) during a COVID-19–related hospitalization is associated with lower all-cause mortality after discharge. The study analyzed patients who survived their initial hospitalization and followed them for up to 29 months to assess long-term outcomes, including mortality, readmission to hospital,…